It has been a privilege and a pleasure to support nearly all of Andreas’s innovations over the past 15 years. The journey from the early days of innovation to today's MultiClot system is not only a testament to technological excellence but also to the persistence of a vision rooted in clinical relevance and collaboration. This new platform represents more than just technical progress—it reflects the collective wisdom of decades of development, multidisciplinary input, and fro

A new article in Diagnostics by Smudla, Schöchl, Andreas Calatzis and colleagues asks an important question in viscoelastic testing: Is “physiological lysis” really plasmin-mediated fibrinolysis? Using the ClotPro system, with APIRO Diagnostics Kft. assays and consumables, the authors compared a tissue factor-activated EX-assay with an AP-assay containing tranexamic acid to inhibit fibrinolysis in 120 healthy adults. The key finding: low maximum lysis values were essentially

A recent single-centre randomised feasibility trial explored ClotPro-guided, low-dose, prolonged systemic thrombolysis for high- and intermediate-high-risk acute pulmonary embolism patients in the ICU. Instead of giving every patient the standard 100 mg rtPA over 2 hours, the viscoelastometry-guided group received an individualised infusion adjusted according to real-time coagulation and fibrinolysis results, alongside repeated echocardiography to monitor right ventricular re